Healthcare / M&A
Gedeon Richter to Buy Mayne Pharma for A$604 Million, Nearly Double Its Last Close
A unanimous board and lined-up holders give the Hungarian buyer a clear first path, if regulators and a prior sale cooperate.
Mayne Pharma has agreed to be bought by Hungary's Gedeon Richter for A$6.40 a share in cash, the Australian drugmaker said Tuesday.
Mayne Pharma announced the scheme on Tuesday in Australia, which was Monday evening in the United States. The buyer is Gedeon Richter, a Hungarian drugmaker listed in Budapest.
Under a scheme implementation deed, Richter would acquire every Mayne share through a new Australian subsidiary. A scheme of arrangement is a court-supervised takeover voted on by shareholders.
A price near double the last close
Richter will pay A$6.40 in cash for each Mayne share. The price values Mayne's equity at about A$604 million.
Reuters converted that value to $407.76 million, at a rate of $1 to A$1.4813. Every other amount in this article is in Australian dollars.
The offer is a 99.4% premium to Mayne's close on Monday, November 16. TickerGrove calculates that the implied closing price was about A$3.21 a share.
It also stands 124% above the 30-day volume-weighted average price, or VWAP. The premiums are 122% over 90 days and 145% over 180 days.
In intraday trading on Tuesday, Mayne shares jumped 86% to A$5.97, a one-year high. Reuters said the stock was on track for its best session on record if the gains held.
That intraday price is not a settled close. It still sat A$0.43 below the offer, a gap of about 6.7%, both TickerGrove calculations.
Unanimous board, a fifth of the register lined up
Mayne's board unanimously recommends the scheme, in the absence of a superior proposal. The support is subject to an independent expert concluding the scheme is in shareholders' best interests.
“The Board’s priority throughout has been to maximise value and certainty for all shareholders,” Chair Bruce Robinson said.
Three large holders have indicated support on the same terms. Funicular Funds holds 9.82%, Bruce Mathieson 6.46% and Trium Capital 5.85%.
Together they hold 22.14% of Mayne's ordinary shares, the announcement said.
No financing condition, several approval conditions
Richter will finance the deal entirely from its internal cash resources. The scheme therefore carries no financing condition.
Completion first requires Mayne to finish selling its International business to Evaris Pharma. That sale is itself a condition of the scheme.
Richter also needs clearance from Australia's Foreign Investment Review Board, known as FIRB. United States antitrust clearance is also required.
Shareholders must approve the scheme, and Australian courts must approve it too. The deal must also avoid specified adverse changes and prescribed occurrences.
Mayne accepted exclusivity restrictions, and Richter holds matching rights over qualifying rival proposals, subject to fiduciary exceptions. A break fee of A$6 million and a matching reverse fee apply in specified circumstances.
Why Richter wants Mayne's U.S. business
Mayne makes branded and generic drugs focused on women's health, dermatology and infectious diseases. After the International sale, its business is focused on the United States.
“Mayne’s existing portfolio – including our estetrol-based innovative combination contraceptive pill – and its commercial footprint provide a strong base to build on,” Deputy Chief Executive László Kovács said.
Kovács said the base would help Richter bring new women's-health treatments to the United States. Richter operates in about 50 countries.
Mayne's U.S. platform includes DistributeRx, a direct-to-patient service launched in March 2026. Women's health and dermatology are its stated growth focus.
The Evaris sale that has to close first
On November 6, Mayne agreed to sell Mayne Pharma International to Evaris Pharma for A$55.5 million in cash. The binding sale was announced to the ASX, Australia's main exchange.
The unit's fiscal 2026 revenue was A$70.7 million, the announcement said. It includes contract manufacturing and the Salisbury facility in South Australia.
The Evaris sale needs approval from the Australian Competition and Consumer Commission, or ACCC. It does not need FIRB approval, and completion is expected in the third quarter of fiscal 2027.
A cleaner ending than the Cosette saga
The Richter deal follows a failed pursuit by Cosette Pharmaceuticals of the United States. Cosette agreed in February 2025 to pay A$7.40 a share, valuing Mayne at A$672 million.
Cosette later sought to walk away, citing a material adverse change in Mayne's business. Australia then blocked the deal last year on national-interest grounds.
Cosette had threatened to shut Mayne's Adelaide plant, which employs about 200 people. The plant is one of Mayne's two main factories.
By Monday's close, Mayne shares had lost more than half their value since Cosette's offer was first announced. The Richter premium is measured against that reduced base.
What remains unknown
Whether the independent expert concludes the scheme is in shareholders' best interests is unknown. The board's recommendation depends on that conclusion holding.
Whether FIRB and United States antitrust regulators clear the acquisition is not yet known. The Evaris sale must also clear the ACCC and complete.
Whether a superior proposal emerges is unknown. Richter's matching rights would shape how Mayne could respond to one.
The approvals that come next
What to watch: the scheme booklet and independent expert's report, expected in mid-December 2026. They follow a first court hearing.
Shareholders are provisionally due to vote in late January 2027. A second court hearing and implementation are targeted for mid-to-late March 2027.
The intraday share price is the live test until then. A wider gap to A$6.40 would signal growing doubt about completion.
Sources & evidence
Source checked3 sources · 15 figures
Figure receipts
Sources
Sources used for this piece.
Small Caps
Mayne Pharma agrees to $604m takeover proposal from Gedeon Richter - Small Caps, Nov. 16, 2026
Reuters
Mayne Pharma
As of Monday, Nov. 16, 2026 (Tuesday, Nov. 17 in Australia).

Discuss this story. Join TickerGrove on Discord to talk companies, earnings, and markets, or request future coverage.

